- Amgen (NASDAQ:AMGN) moves down 2.0% in premarket trading after disclosing new data from the ongoing early-stage study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors.
- The Phase 1 study enrolled 76 patients with KRAS G12C-mutant solid tumors; data presented at the European Society for Medical Oncology 2019 Congress include a subset of 55 evaluable patients as of the July 2019 cutoff.
- Of 29 with colorectal cancer, 12 patients received target dose of 960 mg once daily and 10 remain on treatment; one patient in dose cohort experienced partial response and 10 had stable disease for a disease control rate of 92%.
- For 13 evaluable patients with non-small cell lung cancer, receiving 960 mg, seven (54%) achieved a partial response at one or more timepoints, and six achieved stable disease.
- AMG 510 continues to be well-tolerated with no dose-limiting toxicities.
- Amgen is initiating combination studies to further explore potential of AMG 510 in lung and colorectal tumors.
- Mirati Therapeutics (NASDAQ:MRTX), which has a similar molecule called MRTX849, is falling 2.2% in premarket action.